Archive

Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).

This in vitro study assessed 50 Hz, 100 G extremely low-frequency EMF in combination with temozolomide and radiation in T98 glioblastoma cells grown as monolayers and spheroids. Radiation plus EMF increased apoptosis-related gene expression, while temozolomide plus EMF increased autophagy marker expression compared…

Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53.

This in vitro study evaluated 50 Hz, 70 G electromagnetic field exposure in combination with temozolomide (TMZ) in T98 and A172 glioblastoma cell lines. The authors report that EMF plus TMZ increased cell death and reduced migration potential compared with controls. They also report increased p53 gene expression and…

Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.

This in vitro study evaluated whether extremely low-frequency EMF exposure (100 Hz, 100 G) modifies the effects of temozolomide (100 µM) in human glioblastoma U87 cells over 120–144 hours. The authors report that combined treatment reduced stemness-associated markers (Nestin, CD133, Notch4) and increased GFAP…

Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).

This in vitro study tested whether an extremely low-frequency EMF (100 Hz, 100 G) could enhance temozolomide cytotoxicity in human glioma cell lines (U87 and T98G). The authors report that combined EMF and temozolomide increased apoptosis relative to either treatment alone and was accompanied by changes in…